Close

Brainstorm (BCLI) Says Abstracts on Phase 2 NurOwn Biomarkers Accepted for Presentation at International Symposium on ALS/MND

November 29, 2017 6:31 AM EST Send to a Friend
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login